Related Experiment Videos

Biological activity of Sch 14342, an aminoglycoside antibiotic coproduced in the gentamicin fermentation

Insights

Sch 14342, a gentamicin byproduct, shows similar antibacterial activity but reduced toxicity. This aminoglycoside antibiotic offers a better therapeutic index, particularly for ataxia and renal effects.

Area of Science:

  • Pharmacology
  • Microbiology
  • Drug Development

Background:

  • Gentamicin is a widely used aminoglycoside antibiotic.
  • Sch 14342 is a minor component produced during gentamicin fermentation.
  • Understanding the properties of Sch 14342 is important for potential therapeutic applications.

Purpose of the Study:

  • To compare the efficacy and toxicity of Sch 14342 with gentamicin.
  • To evaluate the therapeutic index of Sch 14342.
  • To assess the potential of Sch 14342 as a therapeutic agent.

Main Methods:

  • In vitro and in vivo antibacterial spectrum analysis.
  • Mouse protection tests to determine relative activity.
  • Acute toxicity, renal toxicity, and ataxia tests in animal models.

Main Results:

  • Sch 14342 demonstrated an equivalent antibacterial spectrum to gentamicin.
  • In vivo, Sch 14342 was approximately one-third as active as gentamicin in mouse protection.
  • Sch 14342 exhibited significantly lower toxicity: 1/3 acute, 1/8 renal, and 1/10 ataxia toxicity compared to gentamicin.

Conclusions:

  • Sch 14342 possesses a comparable antibacterial profile to gentamicin.
  • Sch 14342 offers a substantially improved therapeutic index, especially concerning renal toxicity and ataxia.
  • Sch 14342 represents a promising aminoglycoside antibiotic with enhanced safety.

Related Concept Videos